Visionary Holdings Signs $12M Exclusive Distribution Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy GV?
Visionary Holdings, announced that its wholly owned subsidiary, Visionary Health Technology Group, announced the signing of a $12M exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company, alongside the Board-approved divestiture of its non-core education business.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GV
About GV
Visionary Holdings Inc. is a Canada-based private education provider which offers educational resources to students around the globe. The Company, through its subsidiaries, is primarily engaged in education-related businesses, which include high school education programs, real estate development, animation education, vocational education, online education and other education-related consulting services. Its segments include Rental, Education, Others, Construction and Real Estate. Its businesses include degree-oriented education, vocational education and education services. It offers four levels of degree-oriented education programs, namely OSSD, college, university bachelor’s degree, and master’s degree. It operates education services to support its students enrolled in both the degree-oriented and vocational education programs. Such support includes study visa and immigration visa services, student housing, job placement, and funding.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Visionary Holdings Signs $12 Million Exclusive Agreement
- Exclusive Distribution Agreement: Visionary Holdings' wholly owned subsidiary has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, significantly enhancing market penetration and revenue visibility for its anti-aging product.
- Core Business Focus: The company's board approved the divestiture of 100% equity interests in non-core operations, completing the exit from legacy businesses to concentrate resources on high-margin medical aesthetics and biotechnology innovation, thereby improving capital efficiency and financial flexibility.
- Increased Market Acceptance: The commercialization milestone for Premier Regenerative Complex – President Super Injection signifies the company's formal transition into the high-end medical aesthetics market, reflecting growing market acceptance and bolstering confidence in future revenue growth.
- Management Outlook: The CEO stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-driven growth phase focused on anti-aging injectables and regenerative medical aesthetics, which is expected to drive sustainable expansion and revenue growth.
See More
VISIONARY HOLDINGS' UNIT ENTERS INTO $12 MILLION EXCLUSIVE DISTRIBUTION DEAL WITH HUAJIN CHINA
- Distribution Agreement: Visionary Holdings has signed a $12 million exclusive distribution agreement with Huajin in China.
- Market Expansion: This partnership aims to enhance Visionary Holdings' market presence and distribution capabilities in the Chinese market.
See More
Visionary Holdings Unveils 2026-2027 Strategic Outlook
- International Market Expansion: Visionary Holdings plans to expand its presence in the North American and European medical aesthetics markets from 2026 to 2027 through product commercialization and international distribution partnerships, which is expected to significantly enhance the company's market share in global healthcare services.
- Anti-Aging Product Commercialization: The company anticipates that its RAMU anti-aging product line will become a key revenue growth driver over the next two years, with projected annual sales reaching approximately $30 million, reflecting strong market demand and high-margin potential in the medical aesthetics sector.
- Integrated Healthcare Services Platform Development: Visionary intends to develop an integrated healthcare services platform that combines medical aesthetics products with advanced biotechnology applications, aiming to enhance customer experience and strengthen market competitiveness, thereby driving long-term growth in the healthcare sector.
- Strategic Transition Progress: The CEO stated that Visionary is actively advancing its strategic transition towards healthcare services and aesthetics, with 2026 to 2027 expected to be a crucial stage for product commercialization and international expansion, potentially leading to significant growth opportunities for the company.
See More
Visionary Holdings Signs $12 Million Exclusive Distribution Agreement
- Exclusive Distribution Agreement: Visionary Health Technology Group has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, which is expected to significantly enhance the company's revenue visibility in the high-end medical aesthetics market.
- Core Business Focus: The company's board approved the transfer of 100% equity interests in Visionary Education Services, marking Visionary Holdings' formal exit from non-core education operations, allowing a concentration on anti-aging injectables and regenerative medical aesthetics to improve capital efficiency.
- Increased Market Acceptance: The acceleration of the commercialization process for Premier Regenerative Complex – President Super Injection reflects growing market acceptance, which is anticipated to drive the company's growth in the global medical aesthetics sector.
- Management Strategy: CEO Xiyong Hou stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-centered growth phase focused on high-margin, high-growth medical aesthetics and biotechnology innovation, thereby enhancing financial flexibility.
See More
Visionary Holdings Signs $9 Million Agreement
- Execution Progress: Visionary Holdings Inc.'s wholly owned subsidiary, GV Hong Kong, continues to advance the implementation of a commercial sales agreement valued at approximately $9 million, with expectations to achieve further substantive milestones by the end of Q1 2026, indicating strong operational momentum.
- Service Activities Underway: Since the agreement was signed in September 2025, both parties have been actively working towards contractual milestones, with early-stage service activities in progress, reflecting a growing market demand in high-end health management solutions.
- Product and Service Overview: The agreement encompasses the Premier Regenerative Complex product series and customized VIP health services centered on individualized medical evaluations, aimed at enhancing customer satisfaction through a structured medical oversight framework.
- Management Commentary: CEO Hou Xiyong noted that the ongoing execution of the agreement demonstrates the company's ability to convert strategic partnerships into operational results, emphasizing the importance of compliance-driven revenue recognition and long-term value creation, with positive contributions expected from this business segment to revenue growth and margin profile.
See More
Visionary Holdings Establishes Three Subsidiaries in China
- Regional Market Expansion: Visionary Holdings has established three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu, aimed at enhancing market penetration for its regenerative medicine and aesthetic treatment products through localized market expansion and institutional partnerships, thereby improving overall sales execution efficiency.
- Multi-City Commercial Network: The new subsidiaries complement the company's headquarters in Hangzhou and sales entity in Nanjing, forming a commercialization matrix covering the Shandong Peninsula, Yangtze River Delta, and Anhui region, providing diversified healthcare demand bases and strong institutional resources to optimize market positioning.
- Enhanced Sales Execution Capability: Each subsidiary will focus on building professional sales teams to directly support hospitals and premium wellness institutions while developing strategic partnerships with regional medical providers, ensuring GV's products can smoothly enter the market and achieve sales growth.
- Accelerated Commercialization Process: With the establishment of new subsidiaries, GV has achieved significant milestones over the past year, including global technology licensing and the launch of its anti-aging product portfolio, marking a notable advancement in translating technology assets into structured sales operations.
See More
Visionary Holdings Signs $12 Million Exclusive Agreement
- Exclusive Distribution Agreement: Visionary Holdings' wholly owned subsidiary has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, significantly enhancing market penetration and revenue visibility for its anti-aging product.
- Core Business Focus: The company's board approved the divestiture of 100% equity interests in non-core operations, completing the exit from legacy businesses to concentrate resources on high-margin medical aesthetics and biotechnology innovation, thereby improving capital efficiency and financial flexibility.
- Increased Market Acceptance: The commercialization milestone for Premier Regenerative Complex – President Super Injection signifies the company's formal transition into the high-end medical aesthetics market, reflecting growing market acceptance and bolstering confidence in future revenue growth.
- Management Outlook: The CEO stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-driven growth phase focused on anti-aging injectables and regenerative medical aesthetics, which is expected to drive sustainable expansion and revenue growth.
See More
VISIONARY HOLDINGS' UNIT ENTERS INTO $12 MILLION EXCLUSIVE DISTRIBUTION DEAL WITH HUAJIN CHINA
- Distribution Agreement: Visionary Holdings has signed a $12 million exclusive distribution agreement with Huajin in China.
- Market Expansion: This partnership aims to enhance Visionary Holdings' market presence and distribution capabilities in the Chinese market.
See More
Visionary Holdings Unveils 2026-2027 Strategic Outlook
- International Market Expansion: Visionary Holdings plans to expand its presence in the North American and European medical aesthetics markets from 2026 to 2027 through product commercialization and international distribution partnerships, which is expected to significantly enhance the company's market share in global healthcare services.
- Anti-Aging Product Commercialization: The company anticipates that its RAMU anti-aging product line will become a key revenue growth driver over the next two years, with projected annual sales reaching approximately $30 million, reflecting strong market demand and high-margin potential in the medical aesthetics sector.
- Integrated Healthcare Services Platform Development: Visionary intends to develop an integrated healthcare services platform that combines medical aesthetics products with advanced biotechnology applications, aiming to enhance customer experience and strengthen market competitiveness, thereby driving long-term growth in the healthcare sector.
- Strategic Transition Progress: The CEO stated that Visionary is actively advancing its strategic transition towards healthcare services and aesthetics, with 2026 to 2027 expected to be a crucial stage for product commercialization and international expansion, potentially leading to significant growth opportunities for the company.
See More
Visionary Holdings Signs $12 Million Exclusive Distribution Agreement
- Exclusive Distribution Agreement: Visionary Health Technology Group has signed a $12 million exclusive distribution agreement with Huajin China, establishing a minimum sales target within 12 months, which is expected to significantly enhance the company's revenue visibility in the high-end medical aesthetics market.
- Core Business Focus: The company's board approved the transfer of 100% equity interests in Visionary Education Services, marking Visionary Holdings' formal exit from non-core education operations, allowing a concentration on anti-aging injectables and regenerative medical aesthetics to improve capital efficiency.
- Increased Market Acceptance: The acceleration of the commercialization process for Premier Regenerative Complex – President Super Injection reflects growing market acceptance, which is anticipated to drive the company's growth in the global medical aesthetics sector.
- Management Strategy: CEO Xiyong Hou stated that after extensive strategic evaluation and operational refinement, the company is entering an execution-centered growth phase focused on high-margin, high-growth medical aesthetics and biotechnology innovation, thereby enhancing financial flexibility.
See More
Visionary Holdings Signs $9 Million Agreement
- Execution Progress: Visionary Holdings Inc.'s wholly owned subsidiary, GV Hong Kong, continues to advance the implementation of a commercial sales agreement valued at approximately $9 million, with expectations to achieve further substantive milestones by the end of Q1 2026, indicating strong operational momentum.
- Service Activities Underway: Since the agreement was signed in September 2025, both parties have been actively working towards contractual milestones, with early-stage service activities in progress, reflecting a growing market demand in high-end health management solutions.
- Product and Service Overview: The agreement encompasses the Premier Regenerative Complex product series and customized VIP health services centered on individualized medical evaluations, aimed at enhancing customer satisfaction through a structured medical oversight framework.
- Management Commentary: CEO Hou Xiyong noted that the ongoing execution of the agreement demonstrates the company's ability to convert strategic partnerships into operational results, emphasizing the importance of compliance-driven revenue recognition and long-term value creation, with positive contributions expected from this business segment to revenue growth and margin profile.
See More
Visionary Holdings Establishes Three Subsidiaries in China
- Regional Market Expansion: Visionary Holdings has established three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu, aimed at enhancing market penetration for its regenerative medicine and aesthetic treatment products through localized market expansion and institutional partnerships, thereby improving overall sales execution efficiency.
- Multi-City Commercial Network: The new subsidiaries complement the company's headquarters in Hangzhou and sales entity in Nanjing, forming a commercialization matrix covering the Shandong Peninsula, Yangtze River Delta, and Anhui region, providing diversified healthcare demand bases and strong institutional resources to optimize market positioning.
- Enhanced Sales Execution Capability: Each subsidiary will focus on building professional sales teams to directly support hospitals and premium wellness institutions while developing strategic partnerships with regional medical providers, ensuring GV's products can smoothly enter the market and achieve sales growth.
- Accelerated Commercialization Process: With the establishment of new subsidiaries, GV has achieved significant milestones over the past year, including global technology licensing and the launch of its anti-aging product portfolio, marking a notable advancement in translating technology assets into structured sales operations.
See More
